IVERIC bio (ISEE) Misses Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
March 1, 2023 6:32 AM EST- FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 -
- Post-hoc Time-to-Event Analysis of ACP GATHER Trials Signals up to 59% Risk Reduction in Rate of Vision Loss Compared to Sham at 12 Months
- Commercial Launch Preparations for ACP Continue to Accelerate
- Conference Call and Webcast Today, March 1, 2023, at 8:00 a.m. ET -
PARSIPPANY, N.J.--(BUSINESS... More
